3-May-2024
No headlines found.
OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024
Globe Newswire (Fri, 3-May 8:00 AM ET)
Evertise (Mon, 1-Apr 1:42 PM ET)
Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business
PRNewswire (Thu, 28-Mar 8:00 AM ET)
Globe Newswire (Tue, 5-Mar 8:52 AM ET)
PRNewswire (Wed, 28-Feb 9:31 AM ET)
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
Globe Newswire (Tue, 27-Feb 4:05 PM ET)
OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
Globe Newswire (Thu, 22-Feb 4:05 PM ET)
PRNewswire (Mon, 5-Feb 8:09 AM ET)
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.
Opko Health trades on the NASDAQ stock market under the symbol OPK.
As of May 3, 2024, OPK stock price was flat at $1.30 with 3,273,980 million shares trading.
OPK has a beta of 1.89, meaning it tends to be more sensitive to market movements. OPK has a correlation of 0.08 to the broad based SPY ETF.
OPK has a market cap of $906.09 million. This is considered a Small Cap stock.
Last quarter Opko Health reported $182 million in Revenue and -$.09 earnings per share. This beat revenue expectation by $4 million and met earnings estimates .
In the last 3 years, OPK stock traded as high as $5.25 and as low as $.85.
The top ETF exchange traded funds that OPK belongs to (by Net Assets): IWM, VB, VTI, VXF, IWN.
OPK stock has underperformed the market in the last year with a return of -15.0%, while SPY returned +27.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in OPK shares. However, OPK has outperformed the market in the last 3 month and 2 week periods, returning +30.7% and +5.7%, while SPY returned +3.7% and +3.3%, respectively. This indicates OPK has been having a stronger performance recently.
OPK support price is $1.26 and resistance is $1.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OPK stock will trade within this expected range on the day.